Journal Mobile Options
Table of Contents
Vol. 107, No. 1, 2007
Issue release date: September 2007
Nephron Exp Nephrol 2007;107:e30–e40
(DOI:10.1159/000106775)

Laser Capture Microdissection-Microarray Analysis of Focal Segmental Glomerulosclerosis Glomeruli

Bennett M.R. · Czech K.A. · Arend L.J. · Witte D.P. · Devarajan P. · Potter S.S.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Focal segmental glomerulosclerosis (FSGS) is a major cause of end-stage renal disease. In this report we used laser capture microdissection to purify diseased glomeruli, and microarrays to provide universal gene expression profiles. The results provide a deeper understanding of the molecular mechanisms of the disease process and suggest novel therapeutic strategies. Consistent with earlier studies, molecular markers of the differentiated podocyte, including WT1, nephrin, and VEGF, were dramatically downregulated in the diseased glomerulus. We also observed multiple changes consistent with increased TGF-β signaling, including elevated expression of TGF-β2, TGF-β3, SMAD2, TGF-β1 receptor, and thrombospondin. In addition, there was relatively low level expression of Csf1r, a marker of macrophages, but elevated expression of the chemokines CXCL1, CXCL2, CCL3, and CXCL14. We also observed strongly upregulated expression of Sox9, a transcription factor that can drive a genetic program of chondrogenesis and fibrosis. Further, the gene with the greatest fold increase in expression in the diseased glomerulus was osteopontin, which has been previously strongly implicated in kidney fibrosis in the unilateral ureteral obstruction mouse model. These results confirm old findings, and indicate the involvement of new genetic pathways in the cause and progression of FSGS.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Schnaper HW: Idiopathic focal segmental glomerulosclerosis. Semin Nephrol 2003;23:183–193.
  2. Braden GL, Mulhern JG, O’Shea MH, Nash SV, Ucci AA Jr, Germain MJ: Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000;35:878–883.
  3. Dragovic D, Rosenstock JL, Wahl SJ, Panagopoulos G, DeVita MV, Michelis MF: Increasing incidence of focal segmental glomerulosclerosis and an examination of demographic patterns. Clin Nephrol 2005;63:1–7.
  4. Kitiyakara C, Eggers P, Kopp JB: Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004;44:815–825.
  5. Cattran DC, Rao P: Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998;32:72–79.
  6. Wehrmann M, Bohle A, Held H, Schumm G, Kendziorra H, Pressler H: Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990;33:115–122.
  7. Endlich N, Endlich K: Stretch, tension and adhesion – adaptive mechanisms of the actin cytoskeleton in podocytes. Eur J Cell Biol 2006;85:229–234.
  8. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR: Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000;24:251–256.
  9. Yao J, Le TC, Kos CH, Henderson JM, Allen PG, Denker BM, Pollak MR: Alpha-actinin-4-mediated FSGS: an inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein. PLoS Biol 2004;2:e167.
  10. Kos CH, Le TC, Sinha S, Henderson JM, Kim SH, Sugimoto H, Kalluri R, Gerszten RE, Pollak MR: Mice deficient in α-actinin-4 have severe glomerular disease. J Clin Invest 2003;111:1683–1690.
  11. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C: NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000;24:349–354.
  12. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB: A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005;308:1801–1804.
  13. Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, Miner JH, Shaw AS: Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999;286:312–315.
  14. Huber TB, Kwoh C, Wu H, Asanuma K, Godel M, Hartleben B, Blumer KJ, Miner JH, Mundel P, Shaw AS: Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin. J Clin Invest 2006;116:1337–1345.
  15. Ray PE, Xu L, Rakusan T, Liu XH: A 20-year history of childhood HIV-associated nephropathy. Pediatr Nephrol 2004;19:1075–1092.
  16. Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD: Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498–1509.
  17. Revai T, Kaszas I, Marton C, Arpasi G, Winkler G: Nephrotic syndrome with focal segmental glomerulosclerosis after an insect bite. Clin Nephrol 2006;66:128–130.
  18. Schwimmer JA, Markowitz GS, Valeri AM, Imbriano LJ, Alvis R, D’Agati VD: Secondary focal segmental glomerulosclerosis in non-obese patients with increased muscle mass. Clin Nephrol 2003;60:233–241.
  19. Haraguchi K, Shimura H, Ogata R, Inoue H, Saito T, Kondo T, Nagata M, Kobayashi T: Focal segmental glomerulosclerosis associated with essential thrombocythemia. Clin Exp Nephrol 2006;10:74–77.
  20. Schwab K, Witte DP, Aronow BJ, Devarajan P, Potter SS, Patterson LT: Microarray analysis of focal segmental glomerulosclerosis. Am J Nephrol 2004;24:438–447.
  21. Erkan E, Garcia CD, Patterson LT, Mishra J, Mitsnefes MM, Kaskel FJ, Devarajan P: Induction of renal tubular cell apoptosis in focal segmental glomerulosclerosis: roles of proteinuria and Fas-dependent pathways. J Am Soc Nephrol 2005;16:398–407.
  22. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, et al: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270:27348–27357.
  23. Hristov M, Zernecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A, Weber C: Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007;100:590–597.
  24. Sagrinati C, Netti GS, Mazzinghi B, Lazzeri E, Liotta F, Frosali F, Ronconi E, Meini C, Gacci M, Squecco R, Carini M, Gesualdo L, Francini F, Maggi E, Annunziato F, Lasagni L, Serio M, Romagnani S, Romagnani P: Isolation and characterization of multipotent progenitor cells from the Bowman’s capsule of adult human kidneys. J Am Soc Nephrol 2006;17:2443–2456.
  25. Beirowski B, Weber M, Gross O: Chronic renal failure and shortened lifespan in COL4A3+/– mice: an animal model for thin basement membrane nephropathy. J Am Soc Nephrol 2006;17:1986–1994.
  26. Usui J, Kanemoto K, Tomari S, Shu Y, Yoh K, Mase K, Hirayama A, Hirayama K, Yamagata K, Nagase S, Kobayashi M, Nitta K, Horita S, Koyama A, Nagata M: Glomerular crescents predominantly express cadherin-catenin complex in pauci-immune-type crescentic glomerulonephritis. Histopathology 2003;43:173–179.
  27. Kim JH, Do HJ, Yang HM, Oh JH, Choi SJ, Kim DK, Cha KY, Chung HM: Overexpression of SOX9 in mouse embryonic stem cells directs the immediate chondrogenic commitment. Exp Mol Med 2005;37:261–268.
  28. Tesche F, Miosge N: New aspects of the pathogenesis of osteoarthritis: the role of fibroblast-like chondrocytes in late stages of the disease. Histol Histopathol 2005;20:329–337.
  29. Endlich N, Sunohara M, Nietfeld W, Wolski EW, Schiwek D, Kranzlin B, Gretz N, Kriz W, Eickhoff H, Endlich K: Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress. FASEB J 2002;16:1850–1852.
  30. Hartner A, Porst M, Gauer S, Prols F, Veelken R, Hilgers KF: Glomerular osteopontin expression and macrophage infiltration in glomerulosclerosis of DOCA-salt rats. Am J Kidney Dis 2001;38:153–164.
  31. Yoo KH, Thornhill BA, Forbes MS, Coleman CM, Marcinko ES, Liaw L, Chevalier RL: Osteopontin regulates renal apoptosis and interstitial fibrosis in neonatal chronic unilateral ureteral obstruction. Kidney Int 2006;70:1735–1741.
  32. Kim JH, Kim BK, Moon KC, Hong HK, Lee HS: Activation of the TGF-β/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int 2003;64:1715–1721.
  33. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, Border WA: Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int 1996;49:461–469.
  34. Yoshioka K, Takemura T, Murakami K, Okada M, Hino S, Miyamoto H, Maki S: Transforming growth factor-β protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 1993;68:154–163.
  35. Border WA, Noble NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 1994;331:1286–1292.
  36. Bitzer M, Sterzel RB, Bottinger EP: Transforming growth factor-β in renal disease. Kidney Blood Press Res 1998;21:1–12.
  37. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D: The integrin αvβ6 binds and activates latent TGF-β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999;96:319–328.
  38. Wu K, Yang Y, Wang C, Davoli MA, D’Amico M, Li A, Cveklova K, Kozmik Z, Lisanti MP, Russell RG, Cvekl A, Pestell RG: DACH1 inhibits transforming growth factor-β signaling through binding Smad4. J Biol Chem 2003;278:51673–51684.
  39. McGillicuddy FC, O’Toole D, Hickey JA, Gallagher WM, Dawson KA, Keenan AK: TGF-β1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. Vascul Pharmacol 2006;44:469–475.
  40. Daniel C, Wiede J, Krutzsch HC, Ribeiro SM, Roberts DD, Murphy-Ullrich JE, Hugo C: Thrombospondin-1 is a major activator of TGF-β in fibrotic renal disease in the rat in vivo. Kidney Int 2004;65:459–468.
  41. Hugo C, Kang DH, Johnson RJ: Sustained expression of thrombospondin-1 is associated with the development of glomerular and tubulointerstitial fibrosis in the remnant kidney model. Nephron 2002;90:460–470.
  42. Velosa J, Miller K, Michael AF: Immunopathology of the end-stage kidney. Immunoglobulin and complement component deposition in nonimmune disease. Am J Pathol 1976;84:149–162.
  43. Moll S, Miot S, Sadallah S, Gudat F, Mihatsch MJ, Schifferli JA: No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int 2001;59:160–168.
  44. Huber TB, Reinhardt HC, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstadt H: Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 2002;168:6244–6252.
  45. Vielhauer V, Berning E, Eis V, Kretzler M, Segerer S, Strutz F, Horuk R, Grone HJ, Schlondorff D, Anders HJ: CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 2004;66:2264–2278.
  46. Ghiggeri GM, Bruschi M, Candiano G, Rastaldi MP, Scolari F, Passerini P, Musante L, Pertica N, Caridi G, Ferrario F, Perfumo F, Ponticelli C: Depletion of clusterin in renal diseases causing nephrotic syndrome. Kidney Int 2002;62:2184–2194.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50